Zenosense Inc. (ZENO) Uses Proprietary Technology to Target Multi-Billion Dollar Health Problem

MRSA (Methicillin-resistant Staphylococcus aureus) is a bacterium that has developed a strong resistance to normally prescribed antibiotics, making it especially dangerous. It’s a major problem in hospitals and other environments, and has killed tens of thousands of people in the U.S. alone. One of the challenges is that it can be carried and spread by people without their knowledge. MRSA can be avoided and treated, but the key is quick identification before it gets out of hand. The superbug as it is known comes with a high financial toll for private and public health care systems across the country and elsewhere, but early detection allows protective measures to be implemented.

Zenosense, based in Valencia, Spain, is the holder of an exclusive global license agreement with its co-developer partner, Sgenia Group in Madrid, known for advanced sensor development. Together, the companies are engaged in the creation of a cost-effective MRSA detector system to address the multi-billion MRSA problem. The Sgenia Group has set up a new dedicated subsidiary, Zenon Biosystem (Zenon), contracted to develop the MRSA device for Zenosense. Such a product is expected to be highly attractive to prospective distribution partners and end users, based upon an enormous latent demand for an economical MRSA detector.

Electronic “nose” devices already exist to detect bacteria from cultures. However, these devices are relatively bulky and prohibitively expensive to install on a large scale. There is currently no cost-effective system available for MRSA for detecting infection early in the patient or in the rooms of a healthcare facility. The plan is to base a unique detector on a special sensor technology that Sgenia has already developed. It will detect the Volatile Organic Compounds (VOCs) signature emitted by MRSA. The MRSA VOC signature is only emitted when the bacteria has infected and expressed itself as a disease in the patient, and can be detected prior to the patient being obviously symptomatic, enabling an earlier intervention.

For more information, visit www.zenosense.net

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net